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Biomaterials development for bone repair is currently hindered by the lack of
physiologically relevant in vitro testing systems. Here we describe the novel use of
a bi-directional perfusion bioreactor to support the long term culture of human bone
marrow stromal cells (BMSCs) differentiated on polylactic co-glycolic acid (PLGA).
Primary human BMSCs were seeded onto porous PLGA scaffolds and cultured in
static vs. perfusion culture conditions for 21 days in osteogenic vs. control media.
PLGA scaffolds were osteoconductive, supporting a mature osteogenic phenotype as
shown by the upregulation of Runx2 and the early osteocyte marker E11. Perfusion
culture enhanced the expression of osteogenic genes Osteocalcin and Osteopontin.
Extracellular matrix deposition and mineralisation were spatially regulated within PLGA
scaffolds in a donor dependant manner. This, together with the observed upregulation
of Collagen type X suggested an environment permissive for the study of differentiation
pathways associated with both intramembranous and endochondral ossification routes
of bone healing. This culture system offers a platform to assess BMSC behavior on
candidate biomaterials under physiologically relevant conditions. Use of this system may
improve our understanding of the environmental cues orchestrating BMSC differentiation
and enable fine tuning of biomaterial design as we develop tissue-engineered strategies
for bone regeneration.
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INTRODUCTION
Large bone defects and non-union fracture pose a significant socioeconomic burden, with bone
being the second most transplanted tissue after blood products (Campana et al., 2014). There
is increasing demand for bone grafts globally due to our aging population (Cheung, 2005) and
higher incidence of fractures (Burge et al., 2007; Amin et al., 2014). Current gold standards for
treatment are autologous or allogeneic bone grafts. Autologous bone grafts taken from the iliac
crest are osteoinductive and osteoconductive (Khan et al., 2005). Nevertheless, the size of the graft
is limited (Megas, 2005) and donor site morbidity may be observed (Younger and Chapman, 1989).
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Decellularized allogeneic grafts confer high osteoconductivity
(Finkemeier, 2002), however, pose the risk of adverse immune
responses (Bostrom and Seigerman, 2005) and disease
transmission (Finkemeier, 2002). Thus, focus has turned to
tissue engineering strategies.
A frequently used cell source for tissue engineering bone
are human bone marrow derived stromal cells (BMSCs)
(Arinzeh et al., 2003; van den Dolder et al., 2003; Cinotti
et al., 2004). BMSCs may be culture expanded without losing
their ability to differentiate along the osteogenic lineage
and are able to produce an osseous ECM (Pittenger et al.,
1999). Developmentally and in tissue engineering, bone may
form via two distinct pathways; intramembranous ossification,
whereby BMSCs directly differentiate into osteoblasts and
endochondral ossification, whereby BMSCs first form a cartilage
anlagen which is remodeled and replaced by bone (Gilbert,
2016). The differentiation pathway BMSCs undergo in tissue
engineering is highly dependent on the biochemical, biophysical
and mechanical microenvironment. Thus, there is a need to
establish a physiologically relevant in vitro system for testing
BMSCs responsiveness to biomaterials. As it is known that
cellular behavior in vitro may differ from in vivo behavior,
an in vitro system that effectively recapitulates the in vivo
microenvironment is desirable (Hulsart-Billström et al., 2016).
The first step in achieving this is to culture cells in 3D. The
nature of cell attachment precedes and influences important
events for instance cell migration and differentiation (Baker and
Chen, 2012). In 2D, cell-cell and cell-ECM interactions are held
to a minimum (Baker and Chen, 2012). In terms of biophysical
and biomechanical properties 3D culture also provides a more
physiologically relevant environment compared to 2D. However,
depending upon their size, culturing 3D constructs in static
conditions may lead to cell necrosis in the construct center due
to mass transport limitations (Muschler et al., 2004). Perfusion
culture also mimics interstitial fluid flow in the lacunar and
canalicular spaces of bone (Cowin et al., 1991; Weinbaum et al.,
1994). Thus, by culturing constructs under perfusion, the in
vivo environment is more closely represented and cell survival
may be improved. Shear stress generated from fluid flow is
also an important driver of osteoprogenitor differentiation and
bone cell activity. Perfusion culture of osteoblastic cells increases
alkaline phosphatase activity, Osteopontin secretion and matrix
mineralization (Bancroft et al., 2002). Likewise, shear stress
generated from fluid flow is known to promote the osteogenic
differentiation of BMSCs (McCoy and O’Brien, 2010; Yourek
et al., 2010; Yeatts et al., 2012). In this study we cultured BMSCs
on poly(lactic-co-glycolic acid) (PLGA), which fulfills many
criteria for tissue engineering bone. PLGA is biocompatible, FDA
approved and it is possible tomodify surface properties to achieve
better biocompatibility (Danhier et al., 2012). By using different
scaffold engineering strategies PLGA allows for diverse macro-
and microstructures. Further, PLGA is biodegradable (Gentile
et al., 2014) which is beneficial in order to avoid additional
surgery that would be otherwise necessary for removal.
The aim of the present study was to develop an in
vitro biomaterials testing platform to study the osteogenic
differentiation of primary human BMSCs. The influence of
perfusion culture on BMSC differentiation was investigated by
culturing cells on PLGA scaffolds in a closed system, bidirectional
flow perfusion bioreactor.
MATERIALS AND METHODS
Bone Marrow Stromal Cell Isolation and in
vitro Expansion
Primary BMSCs were isolated from vertebral body bone marrow
aspirates acquired with informed consent and full ethical
approval (KEK Bern 126/03). For the experiments four donors
were used (female 22 years, female 29 years, male 44 years, male
56 years). BMSCs were isolated using Histopaque-1077 (Sigma
Aldrich R©, Switzerland) and density centrifugation as previously
described (Bara et al., 2015). Briefly, after centrifugation the
mononuclear cells present in the interphase were isolated and
counted using a ScepterTM handheld automated cell counter.
Cells were seeded in at a density of ∼50,000 cells/cm2 in growth
media [alpha MEM (Gibco R© Switzerland), 10% fetal calf serum
(SeraPlus, Germany), 1% penicillin and streptomycin (Gibco R©,
Switzerland), 5 ng/ml basic fibroblastic growth factor (Fitzgerald
Industries International, USA)] and cultured at 37◦C and 5%
CO2. After 4 days, growth media was changed 3× per week.
BMSCs were cryopreserved at p1 and stored in liquid nitrogen
prior to use.
PLGA 50:50 Scaffolds
The poly(lactic-co-glycolic acid) scaffolds with a 50:50 ratio
lactic acid vs. glycolic acid (PLGA 50:50) were produced as
previously described (Bardsley et al., 2016). The scaffolds were
8mm in diameter, 2mm height with a pore size of 100–150µm
(Figure 1D). Scaffold degradation was assessed by measuring the
diameter every 7th day of the experiment. Before use, scaffolds
were disinfected by washing for 2 h in 70% Ethanol (Sigma
Aldrich R©, Switzerland) and thereafter, washing in Phosphate
Buffered Saline (PBS) (Sigma Aldrich R©, Switzerland).
Perfusion Bioreactor Culture
The perfusion study was performed using a bidirectional
perfusion flow system U-CUP (CELLEC BIOTEK AG,
Switzerland). BMSCs cultured on scaffolds in static conditions
and as 2D monolayers served as controls. Four million BMSCs
re-suspended in 100 ul were seeded dropwise onto each scaffold
in non-adherent 6-well plates and incubated for 1 h at 37◦C
before 5ml of growth media per scaffold was added. After
24 h, scaffolds were transferred into the U-CUP bioreactor
(Figures 1A,B). Due to holder dimensions and capacity, two
scaffolds per system were cultured in a 10ml volume of control
medium [DMEM low glucose (Gibco R©, Switzerland), 10%
fetal calf serum (Gibco R©, Switzerland), 50µg/ml PrimocinTM
(InvivoGen, France)] vs. osteogenic culture medium [DMEM
low glucose, 10% fetal calf serum, 50µg/ml PrimocinTM, 5mM
Glycerol-2-Phosphate (Sigma Aldrich R©, Switzerland), 50µg/ml
Ascorbic-Acid-2-Phosphate (Sigma Aldrich R©, Switzerland),
10 nM Dexamethasone (Sigma Aldrich R©, Switzerland)].
Oscillating flow in the U-CUP was created by the PHD UltraTM
syringe pump (Havard apparatus, United States). Perfusion
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FIGURE 1 | (A,B) The U-CUP perfusion system. The bidirectional perfusion flow system U-CUP (CELLEC BIOTEK AG, Switzerland) was used to culture PLGA
scaffolds under perfusion. The PHD UltraTM syringe pump (Havard apparatus, United States) created an oscillating flow of media in the U-CUP by pumping air back
and forth. Perfusion velocity for the first 24 h was 400 µm/s, thereafter the velocity was reduced to 100 µm/s. The syringes were connected to the U-CUPs via a
22µm filter to prevent microbes from entering the system. The holder system holding maximum 10 U-CUPs, was placed in the incubator while the syringe pump was
located outside. Two scaffolds per U-CUP were positioned between two silicon scaffold holders in the perfusion scaffold chamber. Each U-CUP was filled with 10ml
of culture media. Media changes were performed via the valves top and below the scaffold chamber. (C) Silicon scaffold holder. Representative picture of a silicon
scaffold holder; scale bar = 2mm. (D) PLGA Scaffold. Representative picture of a PLGA 50:50 scaffold, the scaffolds were 8mm in diameter, 2mm height with a pore
size of 100–150µm; scale bar = 2mm.
velocity for the first 24 h was 400 µm/s, thereafter the velocity
was reduced to 100 µm/s. Scaffolds in the static treatment group
were transferred into new non-adherent 6-well tissue culture
plates 24 h after seeding and each scaffold incubated in a 5ml
volume of control vs. osteogenic culture media. Media changes
were performed 3× per week. Four experiments using a single
BMSC donor per experiment were performed (n = 4). Samples
per group and condition were obtained in triplicate. Samples for
DNA quantification were taken at day 0, 7, and 21. RNA samples
were taken at day 7 and 21. Histological analysis was performed
at 21 days.
Osteogenic Differentiation in Monolayer
BMSCs were seeded at a density of 20,000 cells/cm2 into a 24
well plate on ThermanoxTM coverslips to prevent cell detachment
and cultured in osteogenic vs. control media. Media was changed
three times per week. At day 7 and 21 samples for DNA
quantification and RNA were taken, per group and condition
in triplicates. For Alizarin Red staining on day 21 BMSCs
were washed twice with PBS before fixing with 10% formalin
for 15min. After washing alizarin red stain (40mM; Sigma
Aldrich R©, Switzerland) was applied and incubated for 1 h on a
horizontal shaker at room temperature (RT). Mineralization was
assessed using a light microscope Microscope Axiovert 40 CFL
(Carl Zeiss Microscopy GmbH, Germany).
DNA Quantification
DNA was quantified using Hoechst 33258 (Sigma Aldrich R©,
Switzerland). Scaffolds were digested in 1ml Proteinase K (0,5
mg/ml in PBS containing 10.68 g/l NaH2PO4
∗ 2H2O, 8.45 g/l
Na2HPO4
∗ 7H2O and 3.36 g/l Disodium-EDTA, pH 6.5; Roche
Diagnostics GmbH, Germany) at 56◦C overnight. The remaining
scaffold was removed from the crude homogenate. DNA
standards were prepared using calf thymus DNA (InvitrogenTM,
Switzerland). Standards and samples were diluted 1:5 with the
assay solution containing 1µg/ml Hoechst in PBS. After 15min
incubation in the dark the plate was read using a Perkin Elmer
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TABLE 1 | Primer probe sequences used for real-time PCR with TaqMan method.
Gene Forward 5′-3′ Reverse 5′-3′ Probe 5′-3′
Collagen I 5′-CCC TGG AAA GAA TGG AGA TGA T-3′ 5′-ACT GAA ACC TCT GTG TCC CTT CA-3′ 5′-CGG GCA ATC CTC GAG CAC CCT-3′
Osteocalcin 5′-AAG AGA CCC AGG CGC TAC CT-3′ 5′-AAC TCG TCA CAG TCC GGA TTG-3′ 5′-ATG GCT GGG AGC CCC AGT CCC-3′
Runx2 5′-AGC AAG GTT CAA CGA TCT GAG AT-3′ 5′-TTT GTG AAG ACG GTT ATG GTC AA-3′ 5′-TGA AAC TCT TGC CTC GTC CAC TCC G-3′
Collagen X 5′-ACG CTG AAC GAT ACC AAA TG-3′ 5′-TGC TAT ACC TTT ACT CTT TAT GGT
GTA-3′
5′-ACT ACC CAA CAC CAA GAC ACA GTT CTT
CAT TCC-3′
E11 5′-GGT ACT CGC CCT AAA GAG CTG AA-3′ 5′-GCA CAG AGT CAG AAA CGG TCT TTT-3′ 5′-TTA CGC CCT GCT GCC AAC GTG C-3′
OPN 5′-CTC AGG CCA GTT GCA GCC-3′ 5′-CAA AAG CAA ATC ACT GCA ATT CTC-3′ 5′-AAA CGC CCA AGG AAA ACT CAC TAC C-3′
TABLE 2 | Assay on demand used for real-time PCR with TaqMan method.
Gene Assay ID
18 s 4310893E
ALP Hs00758162_m1
Sox 9 Hs00165814_m1
Viktor3 micro plate reader (Perkin Elmer, United States) at an
excitation of 350 nm and an emission of 450 nm.
Gene Expression Analysis
Three replicate samples per donor were separately processed
and assessed for gene expression. For RNA isolation, samples
were freeze thawed three times and lysed using a tissue
lyser (QIAGEN, Switzerland) with stainless steel balls in TRI
reagent (Molecular Research Center, USA). 10% 1-bromo-3-
chloropropane (BCP) (Sigma Aldrich R©, Switzerland) was added
and the upper aqueous phase precipitated in 70% Ethanol.
RNA was purified using RNeasy spin columns (QIAGEN,
Switzerland) according to manufacturer’s instructions. RNA was
reverse transcribed into cDNA via a high capacity cDNA reverse
transcription kit (Applied Biosystems, Switzerland). Real-time
PCR was performed using Taqman reverse transcription reagent
(life technologiesTM, Switzerland) and the QuantStudioTM 6 Flex
Real-Time PCR System (life technologiesTM, Switzerland). For
primer sequences, see Tables 1, 2. Relative fold change was
calculated with the ddCT method. Normalization was performed
to 18s rRNA and the average CT value of day 7 ThermanoxTM
control samples.
Histology
PLGA scaffolds were fixed in 70% methanol, dehydrated
through an ascending series of ethanol and incubated overnight
in a 1:1 mixture of Histo-Clear and embedded in paraffin
(Sigma Aldrich R©, Switzerland). Sections of 7µm were taken
using a Microm HM 355S microtome (Thermo Scientific,
United States). Sections were dewaxed in Histo-Clear prior to
histological staining. For Hematoxylin and Eosin (H&E), Mayer’s
hematoxylin (Fluka, Switzerland) was applied, blued in tap water
then incubated in 1% Eosin (Fluka, Switzerland). Sections were
dehydrated through graded ethanols, brought into xylene and
mounted with Eukitt (O. Kindler GmbH & Co., Switzerland).
For von Kossa staining a 5% silver nitrate solution (Fluka,
Switzerland) was applied and exposed to strong light. Following
wash steps in 5% sodium thiosulfate and water, sections were
counterstained in 0.1% nuclear fast red (Fluka, Switzerland).
Sections were dehydrated through a series of graded alcohols,
xylene and mounted with Eukitt. Imaging was performed using
an Axioplan 2 Imaging microscope (Carl Zeiss Microscope
GmBH, Germany) equipped with an Axiocam HRc (Carl Zeiss
Microscope GmBH, Germany).
Statistics
Data from individual donors and pooled from four donors (n =
4) are shown. Data for scaffold degradation and DNA content are
presented as medians, error bars represent minimal and maximal
data points. Gene expression data is presented from individual
donors as the mean of three replicate samples ± standard
deviations. Where appropriate statistical analysis was performed
on data pooled from the four donors (n = 4). Statistical analysis
was performed with GraphPad Prism 6 software (GraphPad
Software Inc., La Jolla, CA, USA). Datasets were tested for
normality using the D’Agostino-Pearson test for normality. As all
data were non-normally distributed, the Kruskall-Wallis one-way
analysis of variance test was used to test for differences between
>2 groups. For the comparison between two groups, Mann-
Whitney tests were performed. p-Value <0.05 was considered as
statistically significant.
RESULTS
Long Term Maintenance of BMSC-Seeded
PLGA Scaffolds in a Perfusion Bioreactor
BMSCs were maintained in culture for 21 days on PLGA
scaffolds in the perfusion bioreactor. PLGA gradually degraded
throughout the culture period as shown by decreasing scaffold
diameter (Figure 2A), which was accompanied by a reduction
in total DNA content (Figures 2B,C). As scaffold degradation
proceeded, differentiating BMSCs deposited an extracellular
matrix such that by day 21 a significant quantity of mineralised
extracellular matrix had accumulated within the scaffolds
(Figures 3A,C).
BMSCs Synthesized a Mineralised
Extracellular Matrix Within PLGA Scaffolds
Representative images of extracellular matrix deposition
from two donors are presented. H&E staining confirmed
that independent of culture conditions, BMSCs were evenly
distributed and viable for 21 days when cultured on PLGA
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FIGURE 2 | (A) Scaffold degradation. PLGA scaffolds containing BMSCs
cultured in static conditions in osteogenic vs. control media as indicated were
measured every 7th day of the experiment. Data presented are medians, error
(Continued).
FIGURE 2 | bars represent minimal and maximal data points, n = 6 scaffolds.
(B,C) DNA quantification. BMSCs on PLGA scaffolds were cultured in static
and perfusion conditions in osteogenic vs. control media as indicated.
Samples taken after 7 and 21 days were analyzed using Hoechst. Data
presented are means ± SD, n = 3 technical replicates per donor and
experimental group. *P < 0.05, **P < 0.01, ***P < 0.001.
scaffolds (Figures 3I–P). As indicated by Von Kossa staining,
mineralization took place only in osteogenic media and was
most prominent in the center of the scaffolds (Figures 3A,C).
Mineralisation was generally more prominent in perfusion
conditions (Figure 3A). This mineralisation pattern was
observed in all donors except for one non-mineralizing donor
which failed to mineralize on porous PLGA scaffolds under all
culture conditions (Figures 3B,D,F,H).
Alizarin red staining was performed on BMSCs cultured on
ThermanoxTM, to assess the ability of the cells to mineralize
under osteogenic conditions in monolayer. All donors with the
exception of the non-mineralizing donor mineralized after 21
days in osteogenic media (Figures 4A,C,E). This is in accordance
with PLGA scaffold culture where the same donor also failed
to mineralize. When BMSCs of the non-mineralizing donor
were cultured for an additional week in osteogenic induction
media on ThermanoxTM (day 28) positive Alizarin red staining
could be observed suggesting a slower response of this donor
to osteogenic induction (Figure 4G). No mineralization was
observed in controls of any BMSC donor (Figures 4B,D,F,H).
PLGA Scaffolds and Perfusion Culture
Enhanced the Expression of Osteogenic
Genes and Collagen Type X
Porous PLGA scaffolds promoted osteogenic gene expression as
shown by increases in fold change when compared to day 7
controls cultured on ThermanoxTM. The osteogenic transcription
factor Runx2 was upregulated by BMSCs cultured on PLGA
scaffolds in all conditions at day 7 and 21 (Figures 5A,B).
Sox9 was robustly expressed by BMSCs throughout the culture
period (Figures 5C,D). It has previously been shown that
the Runx2/Sox9 ratio of BMSCs at day 7 is predictive
of the cells mineralising potential at day 21 during 2D
osteogenic differentiation (Loebel et al., 2015). Accordingly,
in 2D conditions on ThermanoxTM the Runx2/Sox9 ratio at
day 7 was higher in osteogenic media compared to control
media (Figure 5F). When cultured on PLGA scaffolds, BMSCs
displayed a high Runx2/Sox9 gene expression ratio in both
osteogenic and control media, supporting its osteoconductive
properties (Figure 5E).
Alkaline Phosphatase was expressed at day 7, increasing by
day 21 in osteogenic groups (Figures 6A,B). Considering data
pooled from all donors, Alkaline Phosphatase was significantly
upregulated in the osteogenic perfusion group compared to the
static control group at day 21 (perfusion osteogenic: 3.25± 1.43-
fold change vs. static control: 0.84± 0.24-fold change, p= 0.0286;
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FIGURE 3 | Histology von Kossa and Hematoxylin Eosin staining. BMSCs on PLGA scaffolds were cultured in perfusion conditions in osteogenic vs. control media as
indicated. Samples were fixed at day 21 and paraffin embedded. Sections were stained with von Kossa or with Hematoxylin Eosin as indicated. Representative
images of a mineralizing donor and a non-mineralizing donor were taken as indicated. Scale bar = 100µm. Von Kossa staining of the perfusion osteogenic group
from (A) mineralizing and (B) non-mineralizing donors. Von Kossa staining of the static osteogenic group from (C) mineralizing and (D) non-mineralizing donors. Von
Kossa staining of the perfusion control group from (E) mineralizing and (F) non-mineralizing donors. Von Kossa staining of the static control group from (G)
mineralizing and (H) non-mineralizing donors. H&E staining of the perfusion osteogenic group from (I) mineralizing and (J) non-mineralizing donors. H&E staining of
the static osteogenic group from (K) mineralizing and (L) non-mineralizing donors. H&E staining of the perfusion control group from (M) mineralizing and (N)
non-mineralizing donors. H&E staining of the static control group from (O) mineralizing and (P) non-mineralizing donors.
Figure 6E). Collagen I was expressed throughout the experiment
with no significant difference between groups (Figures 6C,D).
Osteocalcin and Collagen X demonstrated similar gene
expression patterns. PLGA scaffolds induced expression of
Osteocalcin under all culture conditions at day 7 which
increased in osteogenic perfusion groups in all donors by day
21 (Figures 7A,B). Considering data pooled from all donors,
significant upregulation of Osteocalcin was observed in the
osteogenic perfusion group compared to the control perfusion
group at day 21 (Figure 7E; perfusion osteogenic: 36.37± 18.79-
fold change vs. perfusion control: 1.94 ± 1.46-fold change, p =
0.014). Collagen X expressionwas upregulated in all groups at day
7 and was particularly high in the osteogenic perfusion groups in
all donors at day 21 (Figures 7C,D). When data was pooled from
all donors, significant upregulation of Collagen X was apparent
in the osteogenic perfusion group compared to the control
perfusion group at day 21 (Figure 7F; perfusion osteogenic:
78.17 ± 46.22-fold change vs. perfusion control 3.69 ± 4.36-
fold change, p = 0.0451). A similar pattern but no statistically
significant differences were observed between osteogenic static
and control static groups (Figures 7E,F) for Osteocalcin and
Collagen X pooled donor data.
Osteopontin was expressed at low levels at day 7 in all groups
(Figure 8A). After 21 days Osteopontin was notably upregulated
in the osteogenic perfusion group (Figure 8B). The early
osteocyte marker E11 was upregulated in control and osteogenic
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FIGURE 4 | Alizarin red staining. BMSCs in monolayer on ThermanoxTM cultured in osteogenic vs. control media as indicated. Cells were fixed and stained at day 21
except the non-mineralizing donor B, there the staining was performed at day 28, as after 21 days no mineralization was observed. Representative images of the
osteogenic and the control group were taken. Scale bar = 100µm. Donor A after 21 days of differentiation in (A) osteogenic vs. (B) control media. Donor C after 21
days of differentiation in (C) osteogenic vs. (D) control media. Donor C after 21 days of differentiation in (E) osteogenic vs. (F) control media. Donor B after 28 days of
differentiation in (G) osteogenic vs. (H) control media.
media in all conditions where cells were cultured on porous
PLGA scaffolds throughout the experiment (Figures 8C,D) No
statistically significant differences in either Ell or Osteopontin
gene expression between groups were observed when data from
all donors were combined.
In summary, PLGA scaffold culture demonstrated
osteoconductive properties, as even in control media under
both static and perfusion conditions, osteogenic genes were
upregulated. Perfusion culture further enhanced the expression
of genes associated with a mature osteoblast phenotype in
addition to Collagen X.
DISCUSSION
Our data show that porous PLGA scaffolds and perfusion
conditions provided a favorable environment for the osteogenic
differentiation of BMSCs supporting formation of a mineralised
extracellular matrix. An interesting and novel finding of
this work was that the 3D PLGA perfusion culture system
enhanced the expression of Collagen type X—a gene typically
associated with the hypertrophic chondrocyte phenotype, which
was prominently expressed by cells cultured in the presence
of osteogenic inductive factors (Figures 7C,D,F). Thus, the
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FIGURE 6 | (A–D) Alkaline Phosphatase and Collagen I individual donors gene expression. BMSCs on PLGA scaffolds were cultured in static and perfusion
conditions in osteogenic vs. control media as indicated. Samples taken after 7 and 21 days were analyzed using real time PCR. Relative fold change was calculated
with the ddCT method. Normalization was performed to 18s rRNA and controls cultured on ThermanoxTM at day 7. Data presented are means ± SD, n = 3 technical
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means ± SD, n = 4 donors, *P < 0.05.
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FIGURE 8 | (A–D) Osteopontin and E11 individual donors gene expression BMSCs on PLGA scaffolds were cultured in static and perfusion conditions in osteogenic
vs. control media as indicated. Samples taken after 7 and 21 days were analyzed using real time PCR. Relative fold change was calculated with the ddCT method.
Normalization was performed to 18s rRNA and controls cultured on ThermanoxTM at day 7. Data presented are means ± SD, n = 3 technical replicates per donor
and experimental group.
presented culture system appeared permissive for both direct
and indirect routes of ossification that factor in the remodeling
and healing processes occurring in native adult bone. Further,
we demonstrate the suitability of this bioreactor system as a
biomaterials testing platform to elucidate the important drivers
of BMSC differentiation.
The U-CUP bioreactor successfully supported the long term
culture of primary human BMSCs. This is in accordance with
previous studies where this system was reported to maintain
both freshly isolated and culture expanded marrow stromal
cell populations (Wendt et al., 2003; Braccini et al., 2005;
Papadimitropoulos et al., 2014). Cells cultured on 3D PLGA
scaffolds demonstrated higher osteogenic gene expression when
compared to 2D monolayer. The osteoconductive properties of
the matrix provided by the biomaterial alone were sufficient to
induce osteogenic differentiation, as shown by the upregulation
of OPN and E11 in control media groups (Figures 8A–D).
Osteogenic differentiation on 3D PLGA scaffolds was augmented
further by treatment with osteogenic media under perfusion
culture conditions. The late osteogenic markers Osteocalcin
and Osteopontin which are known to be responsive to shear
stress, were upregulated in BMSCs cultured in osteogenic
media, while perfusion further increased the expression of
these genes (Figures 7A,B,E, 8A,B; Kreke et al., 2005). The
early osteocyte marker E11 was upregulated in all scaffold
groups (Figures 8C,D). In bone, E11 is upregulated in response
to fluid flow and shear stress and associated with increased
dendrite number and length (Schulze et al., 1999; Zhang et al.,
2006). Since E11 was upregulated in both static and perfusion
groups, it suggests that the porous matrix provided by the
PLGA scaffold was permissive for BMSC differentiation toward
a mature osteoblast/early osteocyte phenotype. In the context
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of tissue engineering bone, the presence of OC, OPN and
E11 is highly important to regulate appropriate mineralisation
and tissue maturation. Nitric oxide (NO) and prostaglandin
E2 (PGE2), which are known to be expressed by osteocytes
and BMSCs in response to fluid flow and shear stress (Bakker
et al., 2001) were measured by Elisa, but could not be detected
(data not shown). This may have been due to the frequency
of culture media replacement preventing accumulation up
to detectable levels. Runx2 is a master regulator of BMSC
osteogenic differentiation (Lefebvre and Smits, 2005). It was
previously shown that a high Runx2/Sox9 ratio at day 7 of
osteogenic differentiation is predictive of the osteogenic potential
of BMSCs (Loebel et al., 2015). Data from the current study
where BMSCs were osteogenically differentiated in monolayer
corroborate the Runx2/Sox9 ratio as an osteogenic predictor
(Figure 5F). However, the Runx2/Sox9 ratio at day 7 in cells
cultured on porous PLGA scaffolds did not appear to be
predictive for subsequentmineralization (Figure 5E). As both the
PLGA scaffolds and perfusion culture enhanced the osteogenic
response, the peak of the Runx2/Sox9 ratio may likely have
occurred earlier than day 7. Runx2/Sox9 ratios were higher
in scaffold controls compared to ThermanoxTM controls, again
supporting the osteoconductive properties of PLGA and the
matrix architecture of the scaffolds.
Biomaterials may provide favorable conditions for either
endochondral/intramembranous or indeed both ossification
pathways. In light of this, we also assessed chondrogenic gene
expression in our culture system, however we did not detect
Collagen II nor aggrecan, again their expression might have
peaked at an earlier time point. Additionally, glycosaminoglycans
were not detected in histological nor biochemical analysis
(data not shown). However, the 3D/PLGA perfusion culture
system did induce the expression of Collagen X which was
significantly upregulated in the osteogenic perfusion group at
21 days (Figure 7F). Collagen X is expressed by hypertrophic
chondrocytes in the growth plate (Schmid and Linsenmayer,
1985) but also during fracture healing in the callus (Grant et al.,
1987). It is suggested that Collagen X regulates not only the
mineralization process (Bonen and Schmid, 1991; Kirsch and
Wuthier, 1994) but also provides a suitable matrix for new
bone formation. To our knowledge, assessment of Collagen
X expression during the osteogenic differentiation of primary
human BMSCs has not previously been reported. Collagen X,
in addition to the expression of genes associated with direct
osteogenesis suggests the presence of different cell phenotypes.
We postulate that in the present system, whilst a proportion of
BMSCs underwent direct osteogenic differentiation to mature
osteoblasts, other BMSCs adopted a phenotype more akin to
that of hypertrophic chondrocytes. Innate BMSC heterogeneity
combined with variable micro-environmental conditions within
the constructs could account for this. Differences in mass
transport and fluid dynamics within porous scaffolds will
invariably confer variable environmental conditions experienced
by cells, which may predispose spatial differentiation gradients.
The lineage pathways giving rise to osteoblasts and chondrocytes
during physiological bone healing are not fully understood.
Historically, it was believed hypertrophic chondrocytes in
the cartilage anlagen undergo apoptosis prior to ossification
occurring. However, recent studies present a new hypothesis
that hypertrophic chondrocytes might be capable of trans-
differentiation to osteoblasts (Bahney et al., 2014; Yang et al.,
2014; Houben et al., 2016). The fact that our culture system
allowed for a range of differentiated phenotypes to manifest,
offers the potential to study the finer aspects of BMSC fate
specification.
It is known that osteoblast and osteoprogenitor cell lines
behave differently to primary human BMSCs which limits their
suitability for biomaterials testing—particularly as we strive
to develop autologous, clinical cell-based therapies (Czekanska
et al., 2014). Therefore, we conducted our experiments with
primary human BMSCs from a clinically relevant patient cohort.
As in many studies assessing primary human BMSCs, we
observed donor differences in measured outputs including gene
expression. Donor variation is frequently apparent between
primary BMSC cultures as they are a heterogeneous cell
population derived from bone marrow in an unselected manner.
Pooling BMSCs from different donors prior to an experiment
may reduce variation, but also results in an average population
that does not exist in reality (Stoddart et al., 2012). Thus, we
assessed BMSC populations derived from individual donors in
order to sample a biologically relevant population and maintain
the clinical relevance of our findings. The variation in gene
expression we observed is also partly attributable to the fact
that whole construct analysis was performed which meant that
potential spatial effects on cell behavior were not sufficiently
represented. Hence, histological analysis is an indispensable tool
to reveal spatial differences concerning cell behavior within a 3D
scaffold and to address donor differences.
Three out of four donors formed a mineralized matrix under
osteogenic perfusion conditions. The process of mineralization
in biological tissues requires defined environmental conditions
that are highly regulated. In the case of bone mineralization,
extracellular matrix, namely collagen (Nudelman et al., 2010;
Wang et al., 2012), non-collagenous bone proteins (Roach, 1994)
and minerals are required. The ideal microenvironment for
ossification appears to have been provided in the center of the
scaffolds, as mineralization was predominantly observed there.
A similar process occurs in long bone development, where in
the center of the cartilage anlagen mineralizes to create the
primary ossification center (Gilbert, 2016). It may be that non-
collagenous proteins might be better retained in the scaffold
center, providing optimal conditions for mineralization. The
non-mineralizing donor, which did not mineralize in 3D culture
on PLGA also displayed very low and delayed mineralization
by standard monolayer osteogenesis assay (Figures 3B,D,F,H,
4G). As this donor mineralized less in vitro compared to the
other three donors, it may be that the original bone marrow
sample contained a greater proportion of uncommitted BMSCs
vs. osteoprogenitors/BMSCs with a high mineralizing capacity.
At the gene expression level, the non-mineralizing donor
was not outstanding in terms of less upregulated osteogenic
genes. This discrepancy between what is observed at gene
expressional vs. protein level, highlights the importance of
investigating cellular differentiation using different methods
including those which assess mineral and extracellular matrix
production directly.
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Biomaterials designed for bone regeneration may perform
well when tested in vitro under static conditions, however
may subsequently fail when tested in fracture models (Hulsart-
Billström et al., 2016). This study addressed the unmet need to
develop a more physiologically relevant testing platform by using
primary human cells in a 3D environment and under perfused
conditions.
During human movement bone cells experience a complex
biomechanical environment. In addition to stresses and strains
interstitial fluid flow through the lacunar-canalicular spaces
generates shear stress. Our flow velocity of 100 µm/s was
close to the interstitial fluid flow velocity in human cortical
bone (100 µm/s; Kufahl and Saha, 1990) and mice (80 µm/s;
Zhou et al., 2008). Fluid induced shear stresses range in
the human bone from 0 to 20 dynes/cm2 depending on the
cellular location (Mi et al., 2005a,b). However, as our porous
scaffold contained highly irregular geometries non-uniform flow
patterns could be expected inside the scaffold. Thus, shear
stress variations greater than one order of magnitude could
be expected even when constant flow velocities are applied
(Boschetti et al., 2006; Jungreuthmayer et al., 2009). In addition to
the biochemistry and the mechanical environment of a scaffold,
matrix architecture plays a tremendous role in driving cellular
differentiation (Melchels et al., 2010; Saito et al., 2013). In the
present study, several characteristics may have contributed to
the osteoinductive properties of the PLGA scaffolds including
pore size. The pore size of our salt-leached scaffolds ranged
between 100 and 150µm which is similar to the pore size of
the Haversian canals in human cortical bone (Wang and Ni,
2003). The suitability of this pore size for bone ingrowth was
previously determined in 1971 by Klawitter and Hulbert (1971)
and has been successfully confirmed by others with the use
of micro-CT (Jones et al., 2007). There are other features of
the scaffolds that may have influenced BMSC differentiation
including surface topography and stiffness. BMSCs cultured
in our 3D culture system would have experienced different
stiffnesses depending upon their location. For example cells
adhered directly to the biomaterial vs. cells encapsulated in
extracellular matrix within a scaffold pore. A stiff substrate
is known to direct BMSCs toward osteogenic differentiation
(Engler et al., 2006). This has the advantage that the process
is faster in contrary to natural healing process of long bones
whereby a cartilage intermediate is formed initially. However,
stiff biomaterials often fail in vivo, as fast matrix deposition
combined with a lack of vascularization limits nutrient and gas
exchange (Nomi et al., 2002; Ko et al., 2007; Thompson et al.,
2015). Therefore, attention has turned toward softer substrates
and creating an environment favorable for chondrogenesis
(Dennis et al., 2015; Thompson et al., 2015). The endochondral
ossification route is a lengthier process, but chondrocytes are
larger compared to osteoblasts and thus the fracture gap is
bridged quicker. Further, the endochondral ossification has the
advantage that hypertrophic chondrocytes are known to secrete
a wide range of soluble osteogenic and angiogenic factors thus
promoting vascular invasion of the tissue (Mackie et al., 2011).
Our culture system appeared permissive in supporting BMSC
differentiation pathways involved in both intramembranous
and endochondral ossification. A tissue engineered construct
combining the advantages of both ossification routes could
be very favorable in mediating rapid and functional bone
regeneration.
How BMSC-seeded PLGA scaffolds would perform in vivo
requires further investigation. It is desirable that materials
implanted into bone defects degrade at a suitable rate to allow
new matrix deposition, mineralisation and vascular ingrowth
to take place. The degradation of PLGA in this study supports
previous observations using these scaffolds (Bardsley et al., 2016).
PLGA degradation rate may be modified by adjusting internal
factors; ratio of glycolic vs. lactic portion, porosity, size etc (Lu
et al., 1999; Wu and Ding, 2005; Makadia and Siegel, 2011)
and external factors; local pH, mechanical loading, temperature
(Middleton and Tipton, 2000; Grayson et al., 2005; Yang et al.,
2010). Ultimately, the success of a tissue engineering strategy
for bone repair require testing using an appropriate pre-clinical
model. Factors, such as mechanical loading, paracrine signaling
between cell types, the periosteum and the immune system all
play a tremendous role in fracture healing (Dwek, 2010; Marsell
and Einhorn, 2011).
In conclusion, we report the novel use of a perfusion
bioreactor for the osteogenic differentiation of primary human
BMSCs on porous PLGA scaffolds. Our 3D culture system
supported long term culture and promoted osteogenesis via both
direct and indirect ossification routes. The design features of the
bioreactor offer the possibility to screen multiple biomaterials
in parallel and under controlled conditions. The opportunity
to investigate the finer aspects of BMSC differentiation under
more physiological conditions may improve our understanding
of the micro-environmental cues governing BMSC fate. This
may in turn help us to understand the causes of non-union
fracture, identify mechanistic targets and enable the fine-tuning
of biomaterial design in order to deliver reliable tissue engineered
approaches for bone repair.
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